article thumbnail

Roche bets on Ionis RNA medicines with neuroscience deal

Bio Pharma Dive

The Swiss drugmaker is restocking its pipeline by buying into preclinical Ionis medicines for Alzheimer’s and Huntington’s diseases.

Medicine 285
article thumbnail

Orbital raises $270m investment for advancement of RNA medicines

Pharmaceutical Technology

Orbital Therapeutics has raised $270m in a Series A round led by ARCH Venture Partners to advance a portfolio of programmable RNA therapeutics. Orbital will use the new funding to increase the application of RNA-based medicines for use in the fields of new vaccines, immunomodulation and protein replacement.

RNA 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Next-generation RNA technologies: making longer-lasting drugs with a broader reach

Bio Pharma Dive

At least 10 biotechnology startups are trying to use RNA molecules in new ways to make medicines. Here’s a look at where they stand.

RNA 324
article thumbnail

Moderna founder unveils new drug company focused on a different kind of RNA

Bio Pharma Dive

The biotech is researching how to make medicines from transfer RNA molecules. Encouraged by Moderna's success, Flagship Pioneering has been busy creating startups like Alltrna, which launched Tuesday.

RNA 358
article thumbnail

Wave readies clinical testing for first RNA editing therapy

Bio Pharma Dive

The biotech, one of several advancing RNA editing medicines, expects to obtain “proof-of-mechanism” data in patients with the inherited disorder alpha-1 antitrypsin deficiency by next year.

RNA 168
article thumbnail

New UK intracellular drug delivery centre to support RNA development

Pharmaceutical Technology

A new intracellular drug delivery centre will be established in the UK to support potential ribonucleic acid (RNA) vaccines and therapeutics , as well as the development of innovative drug delivery technologies. The funding is being provided under the agency’s Transforming Medicines Manufacturing programme.

article thumbnail

Venture capital pours more money into RNA medicines with the launch of Replicate

Bio Pharma Dive

The company, which focuses on self-replicating RNA, comes equipped with $40 million from Apple Tree Partners and a stamp of approval from the former research head at Biogen.

RNA 270